1. Ford ES. Trends in mortality from COPD among adults in the United States. Chest. 2015. 148(4): 962-970. doi: http://dx.doi.org/10.1378/chest.14-2311
2. Ford ES. Hospital discharges, readmissions, and ED visits for COPD or bronchiectasis among US adults: findings from the Nationwide Inpatient Sample 2001-2012 and Nationwide Emergency Department Sample 2006-2011. Chest. 2015. 147(4): 989-998. doi:http://dx.doi.org/10.1378/chest.14-2146
3. Liu Y, Pleasants RA, Croft JB, et al. Smoking duration, respiratory symptoms, and COPD in adults aged ≥45 years with a smoking history. Int J Chron Obstruct Pulmon Dis. 2015. 10: 1409-1416. doi: http://dx.doi.org/10.2147/COPD.S82259
4. Carlin BW. COPD and associated comorbidities: a review of current diagnosis and treatment. Postgrad Med. 2012. 124(4): 225-240. doi: http://dx.doi.org/10.3810/pgm.2012.07.2582
5. Mapel DW, Dalal AA, Johnson P, Becker L, Hunter AG. A clinical study of COPD severity assessment by primary care physicians and their patients compared with spirometry. Am J Med. 2015. 128(6): 629-637. doi: http://dx.doi.org/10.1016/j.amjmed.2014.12.018
6. Make B, Dutro MP, Paulose-Ram R, Marton JP, Mapel DW. Undertreatment of COPD: a retrospective analysis of US managed care and Medicare patients. Int J Chron Obstruct Pulmon Dis. 2012. 7: 1-9. doi: http://dx.doi.org/10.2147/COPD.S27032
7. Leidy NK, Kim K, Bacci ED, et al. Identifying cases of undiagnosed, clinically significant COPD in primary care: qualitative insight from patients in the target population. NPJ Prim Care Respir Med. 2015. 25: 15024. doi: http://dx.doi.org/10.1038/npjpcrm.2015.24
8. Ingebrigtsen TS, Marott JL, Nordestgaard BG, et al. Low use and adherence to maintenance medication in chronic obstructive pulmonary disease in the general population. J Gen Intern Med. 2015. 30(1): 51-59. doi: http://dx.doi.org/10.1007/s11606-014-3029-0
9. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005. 127(1): 335-371. doi: http://dx.doi.org/10.1378/chest.127.1.335
10. Dal Negro RW, Bonadiman L, Tognella S, Bricolo FP, Turco P. Extent and prevalence of cognitive dysfunction in chronic obstructive pulmonary disease, chronic non-obstructive bronchitis, and in asymptomatic smokers, compared to normal reference values. Int J Chron Obstruct Pulmon Dis. 2014. 9: 675-683. doi: http://dx.doi.org/10.2147/COPD.S63485
11. Dodd JW. Lung disease as a determinant of cognitive decline and dementia. Alzheimers Res Ther. 2015. 7(1): 32. doi: http://dx.doi.org/10.1186/s13195-015-0116-3
12. Sachdev PS, Anstey KJ, Parslow RA, et al. Pulmonary function, cognitive impairment and brain atrophy in a middle-aged community sample. Dement Geriatr Cogn Disord. 2006. 21(5-6): 300-308. doi: http://dx.doi.org/10.1159/000091438
13. Singh B, Mielke MM, Parsaik AK, et al. A prospective study of chronic obstructive pulmonary disease and the risk for mild cognitive impairment. JAMA Neurol. 2014. 71(5): 581-588. doi: http://dx.doi.org/10.1001/jamaneurol.2014.94
14. GOLD Guidelines Committee. Global Initiative for Chronic Obstructive Lung Disease: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. GOLD website. http://www.goldcopd.org. Published 2004. Updated 2016. Accessed November 2016
15. Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008. 5(4): 549-555. doi: http://dx.doi.org/10.1513/pats.200709-148ET
16. Jarvis S, Ind PW, Shiner RJ. Inhaled therapy in elderly COPD patients; time for re-evaluation? Age Ageing. 2007. 36(2): 213-218. doi: http://dx.doi.org/10.1093/ageing/afl174
17. Quinet P, Young CA, Heritier F. The use of dry powder inhaler devices by elderly patients suffering from chronic obstructive pulmonary disease. Ann Phys Rehabil Med. 2010. 53(2): 69-76. doi: http://dx.doi.org/10.1016/j.rehab.2009.11.001
18. Mahler DA, Waterman LA, Gifford AH. Prevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the Diskus® dry powder inhaler. J Aerosol Med Pulm Drug Deliv. 2013. 26(3): 174-179. doi: http://dx.doi.org/10.1089/jamp.2012.0987
19. Grant I, Heaton RK, McSweeny AJ, Adams KM, Timms RM. Neuropsychologic findings in hypoxemic chronic obstructive pulmonary disease. Arch Intern Med. 1982. 142(8): 1470-1476.
20. Dodd JW, Getov SV, Jones PW. Cognitive function in COPD. Eur Respir J. 2010. 35(4): 913-922. doi: http://dx.doi.org/10.1183/09031936.00125109
21. Ortapamuk H, Naldoken S. Brain perfusion abnormalities in chronic obstructive pulmonary disease: comparison with cognitive impairment. Ann Nucl Med. 2006. 20(2): 99-106.
22. Dodd JW, Chung AW, van den Broek MD, Barrick TR, Charlton RA, Jones PW. Brain structure and function in chronic obstructive pulmonary disease: a multimodal cranial magnetic resonance imaging study. Am J Respir Crit Care Med. 2012. 186(3): 240-245. doi: http://dx.doi.org/10.1164/rccm.201202-0355OC
23. Grant I, Prigatano GP, Heaton RK, McSweeny AJ, Wright EC, Adams KM. Progressive neuropsychologic impairment and hypoxemia. Relationship in chronic obstructive pulmonary disease. Arch Gen Psychiatry. 1987. 44(11): 999-1006.
24. Thakur N, Blanc PD, Julian LJ, et al. COPD and cognitive impairment: the role of hypoxemia and oxygen therapy. Int J Chron Obstruct Pulmon Dis. 2010. 5: 263-269.
25. Singh B, Parsaik AK, Mielke MM, et al. Chronic obstructive pulmonary disease and association with mild cognitive impairment: the Mayo Clinic Study of Aging. Mayo Clin Proc. 2013. 88(11): 1222-1230. doi: http://dx.doi.org/10.1016/j.mayocp.2013.08.012
26. Seemungal TA, Hurst JR, Wedzicha JA. Exacerbation rate, health status and mortality in COPD--a review of potential interventions. Int J Chron Obstruct Pulmon Dis. 2009. 4: 203-223.
27. Hurst JR, Donaldson GC, Quint JK, Goldring JJ, Baghai-Ravary R, Wedzicha JA. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009. 179(5): 369-374. doi: http://dx.doi.org/10.1164/rccm.200807-1067OC
28. Donaldson GC, Law M, Kowlessar B, et al. Impact of prolonged exacerbation recovery in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015. 192(8): 943-950. doi: http://dx.doi.org/10.1164/rccm.201412-2269OC
29. Halpin DM, Decramer M, Celli B, Kesten S, Liu D, Tashkin DP. Exacerbation frequency and course of COPD. Int J Chron Obstruct Pulmon Dis. 2012. 7: 653-661. doi: http://dx.doi.org/10.2147/COPD.S34186
30. Stevenson NJ, Walker PP, Costello RW, Calverley PM. Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005. 172(12): 1510-1516. doi: http://dx.doi.org/10.1164/rccm.200504-595OC
31. Cooper CB, Barjaktarevic I. A new algorithm for the management of COPD. Lancet Respir Med. 2015. 3(4): 266-268. doi: http://dx.doi.org/10.1016/S2213-2600(15)00091-0
32. O'Reilly JF, Williams AE, Holt K, Rice L. Defining COPD exacerbations: impact on estimation of incidence and burden in primary care. Prim Care Respir J. 2006. 15(6): 346-353. doi: http://dx.doi.org/10.1016/j.pcrj.2006.08.009
33. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010. 363(12): 1128-1138. doi: http://dx.doi.org/10.1056/NEJMoa0909883
34. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med. 2009. 360(14): 1418-1428. doi: http://dx.doi.org/10.1056/NEJMsa0803563
35. Elixhauser A, Au DH, Podulka J. Readmissions for Chronic Obstructive Pulmonary Disease, 2008: Statistical Brief #121. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville (MD)2006.
36. Hurst JR, Wedzicha JA. Management and prevention of chronic obstructive pulmonary disease exacerbations: a state of the art review. BMC Med. 2009. 7: 40. doi: http://dx.doi.org/10.1186/1741-7015-7-40
37. Melzer AC, Feemster LM, Uman JE, Ramenofsky DH, Au DH. Missing potential opportunities to reduce repeat COPD exacerbations. J Gen Intern Med. 2013. 28(5): 652-659. doi: http://dx.doi.org/10.1007/s11606-012-2276-1
38. Lu N, Huang KC, Johnson JA. Reducing excess readmissions: promising effect of hospital readmissions reduction program in US hospitals. Int J Qual Health Care. 2015. doi: http://dx.doi.org/10.1093/intqhc/mzv090
39. Prieto-Centurion V, Markos MA, Ramey NI, et al. Interventions to reduce rehospitalizations after chronic obstructive pulmonary disease exacerbations. A systematic review. Ann Am Thorac Soc. 2014. 11(3): 417-424. doi: http://dx.doi.org/10.1513/AnnalsATS.201308-254OC
40. Krishnan JA, Gussin HA, Prieto-Centurion V, Sullivan JL, Zaidi F, Thomashow BM. Integrating COPD into patient-centered hospital readmissions reduction programs. Chronic Obstr Pulm Dis (Miami). 2015. 2(1): 70-80. doi: http://dx.doi.org/10.15326/jcopdf.2.1.2014.0148
41. Rennard S, Thomashow B, Crapo J, et al. Introducing the COPD Foundation Guide for Diagnosis and Management of COPD, recommendations of the COPD Foundation. COPD. 2013. 10(3): 378-389. doi: http://dx.doi.org/10.3109/15412555.2013.801309
42. Shah T, Churpek MM, Coca Perraillon M, Konetzka RT. Understanding why patients with COPD get readmitted: a large national study to delineate the Medicare population for the readmissions penalty expansion. Chest. 2015. 147(5): 1219-1226. doi: http://dx.doi.org/10.1378/chest.14-2181
43. Sharma G, Kuo YF, Freeman JL, Zhang DD, Goodwin JS. Outpatient follow-up visit and 30-day emergency department visit and readmission in patients hospitalized for chronic obstructive pulmonary disease. Arch Intern Med. 2010. 170(18): 1664-1670. doi: http://dx.doi.org/10.1001/archinternmed.2010.345
44. Sharif R, Parekh TM, Pierson KS, Kuo YF, Sharma G. Predictors of early readmission among patients 40 to 64 years of age hospitalized for chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014. 11(5): 685-694. doi: http://dx.doi.org/10.1513/AnnalsATS.201310-358OC
45. Baker CL, Zou KH, Su J. Risk assessment of readmissions following an initial COPD-related hospitalization. Int J Chron Obstruct Pulmon Dis. 2013. 8: 551-559. doi: http://dx.doi.org/10.2147/copd.s51507
46. Niewoehner DE, Lokhnygina Y, Rice K, et al. Risk indexes for exacerbations and hospitalizations due to COPD. Chest. 2007. 131(1): 20-28. doi: http://dx.doi.org/10.1378/chest.06-1316
47. Chawla H, Bulathsinghala C, Tejada JP, Wakefield D, ZuWallack R. Physical activity as a predictor of thirty-day hospital readmission after a discharge for a clinical exacerbation of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014. 11(8): 1203-1209. doi: http://dx.doi.org/10.1513/AnnalsATS.201405-198OC
48. Yu TC, Zhou H, Suh K, Arcona S. Assessing the importance of predictors in unplanned hospital readmissions for chronic obstructive pulmonary disease. Clinicoecon Outcomes Res. 2015. 7: 37-51. doi: http://dx.doi.org/10.2147/CEOR.S74181
49. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000. 161(5): 1608-1613. doi: http://dx.doi.org/10.1164/ajrccm.161.5.9908022
50. Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest. 2003. 124(2): 459-467.
51. Barr RG, Celli BR, Mannino DM, et al. Comorbidities, patient knowledge, and disease management in a national sample of patients with COPD. Am J Med. 2009. 122(4): 348-355. doi: http://dx.doi.org/10.1016/j.amjmed.2008.09.042
52. Diette GB, Dalal AA, D'Souza AO, Lunacsek OE, Nagar SP. Treatment patterns of chronic obstructive pulmonary disease in employed adults in the United States. Int J Chron Obstruct Pulmon Dis. 2015. 10: 415-422. doi: http://dx.doi.org/10.2147/COPD.S75034
53. Sharafkhaneh A, Altan AE, Colice GL, et al. A simple rule to identify patients with chronic obstructive pulmonary disease who may need treatment reevaluation. Respir Med. 2014. 108(9): 1310-1320. doi: http://dx.doi.org/10.1016/j.rmed.2014.07.002
54. Bollu V, Ejzykowicz F, Rajagopalan K, Karafilidis J, Hay JW. Risk of all-cause hospitalization in COPD patients initiating long-acting or short-acting beta agonist therapy. J Med Econ. 2013. 16(8): 1082-1088. doi: http://dx.doi.org/10.3111/13696998.2013.815625
55. Cooper CB, Celli BR, Jardim JR, et al. Treadmill endurance during 2-year treatment with tiotropium in patients with COPD: a randomized trial. Chest. 2013. 144(2): 490-497. doi: http://dx.doi.org/10.1378/chest.12-2613
56. Casaburi R, Kukafka D, Cooper CB, Witek TJ, Jr., Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest. 2005. 127(3): 809-817. doi: http://dx.doi.org/10.1378/chest.127.3.809
57. Braido F, Baiardini I, Cazzola M, Brusselle G, Marugo F, Canonica GW. Long-acting bronchodilators improve health related quality of life in patients with COPD. Respir Med. 2013. 107(10): 1465-1480. doi: http://dx.doi.org/10.1016/j.rmed.2013.08.007
58. Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011. 105(6): 930-938. doi: http://dx.doi.org/10.1016/j.rmed.2011.01.005
59. Souza ML, Meneghini AC, Ferraz E, Vianna EO, Borges MC. Knowledge of and technique for using inhalation devices among asthma patients and COPD patients. J Bras Pneumol. 2009. 35(9): 824-831.
60. Press VG, Arora VM, Shah LM, et al. Misuse of respiratory inhalers in hospitalized patients with asthma or COPD. J Gen Intern Med. 2011. 26(6): 635-642. doi: http://dx.doi.org/10.1007/s11606-010-1624-2
61. Press VG, Arora VM, Trela KC, et al. Effectiveness of interventions to teach metered-dose and diskus inhaler techniques. A randomized trial. Ann Am Thorac Soc. 2016. 13(6): 816-824. doi: http://dx.doi.org/10.1513/AnnalsATS.201509-603OC
62. Vanderman AJ, Moss JM, Bailey JC, Melnyk SD, Brown JN. Inhaler misuse in an older adult population. Consult Pharm. 2015. 30(2): 92-100. doi: http://dx.doi.org/10.4140/TCP.n.2015.92
63. Melani AS, Zanchetta D, Barbato N, et al. Inhalation technique and variables associated with misuse of conventional metered-dose inhalers and newer dry powder inhalers in experienced adults. Ann Allergy Asthma Immunol. 2004. 93(5): 439-446.
64. Mitchell JP, Nagel MW. Valved holding chambers (VHCs) for use with pressurised metered-dose inhalers (pMDIs): a review of causes of inconsistent medication delivery. Prim Care Respir J. 2007. 16(4): 207-214. doi: http://dx.doi.org/10.3132/pcrj.2007.00034
65. Rau JL. The inhalation of drugs: advantages and problems. Respir Care. 2005. 50(3): 367-382.
66. Dhand R, Dolovich M, Chipps B, Myers TR, Restrepo R, Farrar JR. The role of nebulized therapy in the management of COPD: evidence and recommendations. COPD. 2012. 9(1): 58-72. doi: http://dx.doi.org/10.3109/15412555.2011.630047
67. Dolovich MB, Dhand R. Aerosol drug delivery: developments in device design and clinical use. Lancet. 2011. 377(9770): 1032-1045. doi: http://dx.doi.org/10.1016/S0140-6736(10)60926-9
68. Stevens N. Inhaler devices for asthma and COPD: choice and technique. Prof Nurse. 2003. 18(11): 641-645.
69. Malmberg LP, Rytila P, Happonen P, Haahtela T. Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters. Int J Chron Obstruct Pulmon Dis. 2010. 5: 257-262.
70. Janssens W, VandenBrande P, Hardeman E, et al. Inspiratory flow rates at different levels of resistance in elderly COPD patients. Eur Respir J. 2008. 31(1): 78-83. doi: http://dx.doi.org/10.1183/09031936.00024807
71. Wheaton AG, Ford ES, Cunningham TJ, Croft JB. Chronic obstructive pulmonary disease, hospital visits, and comorbidities: National Survey of Residential Care Facilities, 2010. J Aging Health. 2015. 27(3): 480-499. doi: http://dx.doi.org/10.1177/0898264314552419
72. Sharafkhaneh A, Wolf RA, Goodnight S, Hanania NA, Make BJ, Tashkin DP. Perceptions and attitudes toward the use of nebulized therapy for COPD: patient and caregiver perspectives. COPD. 2013. 10(4): 482-492. doi: http://dx.doi.org/10.3109/15412555.2013.773302
73. Mahler DA, Waterman LA, Ward J, Gifford AH. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate. J Aerosol Med Pulm Drug Deliv. 2014. 27(2): 103-109. doi: http://dx.doi.org/10.1089/jamp.2013.1038
74. Leaker BR, Barnes PJ, Jones CR, Tutuncu A, Singh D. Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease. Br J Clin Pharmacol. 2015. 79(3): 492-500. doi: http://dx.doi.org/10.1111/bcp.12517
75. Pulido-Rios MT, McNamara A, Obedencio GP, et al. In vivo pharmacological characterization of TD-4208, a novel lung-selective inhaled muscarinic antagonist with sustained bronchoprotective effect in experimental animal models. J Pharmacol Exp Ther. 2013. 346(2): 241-250. doi: http://dx.doi.org/10.1124/jpet.113.203554
76. O'Driscoll BR, Kay EA, Taylor RJ, Weatherby H, Chetty MC, Bernstein A. A long-term prospective assessment of home nebulizer treatment. Respir Med. 1992. 86(4): 317-325.
77. Godden DJ, Robertson A, Currie N, Legge JS, Friend JA, Douglas JG. Domiciliary nebuliser therapy--a valuable option in chronic asthma and chronic obstructive pulmonary disease? Scott Med J. 1998. 43(2): 48-51.
78. Corden ZM, Bosley CM, Rees PJ, Cochrane GM. Home nebulized therapy for patients with COPD: patient compliance with treatment and its relation to quality of life. Chest. 1997. 112(5): 1278-1282.
79. Chen YJ, Makin C, Bollu VK, Navaie M, Celli BR. Exacerbations, health services utilization, and costs in commercially-insured COPD patients treated with nebulized long-acting β2-agonists. J Med Econ. 2016. 19(1): 11-20. doi: http://dx.doi.org/10.3111/13696998.2015.1079530
80. Barta SK, Crawford A, Roberts CM. Survey of patients' views of domiciliary nebuliser treatment for chronic lung disease. Respir Med. 2002. 96(6): 375-381.
81. Alhaddad B, Smith FJ, Robertson T, Watman G, Taylor KM. Patients' practices and experiences of using nebuliser therapy in the management of COPD at home. BMJ Open Respir Res. 2015. 2(1): e000076. doi: http://dx.doi.org/10.1136/bmjresp-2014-000076
82. Boe J, Dennis JH, O'Driscoll BR, et al. European Respiratory Society Guidelines on the use of nebulizers. Eur Respir J. 2001. 18(1): 228-242.
83. Sims MW. Aerosol therapy for obstructive lung diseases: device selection and practice management issues. Chest. 2011. 140(3): 781-788. doi: http://dx.doi.org/10.1378/chest.10-2068
84. Celli BR, Decramer M, Wedzicha JA, et al. An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015. 191(7): e4-e27. doi: http://dx.doi.org/10.1164/rccm.201501-0044ST
85. Olodaterol (Striverdi Respimat) for COPD. Med Lett Drugs Ther. 2015. 57(1459): 1-3.